comprimé enrobé

DRUG8 trials

Sponsors

University Hospital Of Clermont-Ferrand, Assistance Publique Hopitaux De Paris, Centre Hospitalier Regional Universitaire, Brenus Pharma, Centre Leon Berard

Conditions

Idiopathic osteoarthritis of the hip or kneeMetastatic colorectal cancerPatients with locally advanced or metastatic low grade endometrial stroma sarcomaUnresectable locally advanced or metastatic colorectal cancerWomen who delivered by caesarean and have a moderate postpartum iron deficiency anaemia defined by 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL within 72h after delivery and a ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% (Measured after postoperative Hb level measurement)and pan-uveitismetastatic colorectal cancer carcinomaposterior

Phase 1

Open label, multicenter dose-escalation and cohort-expansion phase I/IIA trial of STC-1010, an immunotherapy, in patients with unresectable locally advanced or metastatic colorectal cancer (CRC) - BreAK CRC trial (BreAK for Brenus Anti-cancer).

RecruitingCTIS2024-512011-45-00

Brenus PharmaUnresectable locally advanced or metastatic colorectal cancer

Start: 2025-06-17Target: 79Updated: 2025-10-06

Phase 2

BFR ESS - A randomized comparative, prospective, multicentre phase II study evaluating the clinical impact of interruption versus maintenance of aromatase inhibitors in patients with locally advanced or metastatic low grade endometrial stromal sarcoma

RecruitingCTIS2024-512629-97-00

Centre Leon BerardPatients with locally advanced or metastatic low grade endometrial stroma sarcoma

Start: 2019-01-23Target: 40Updated: 2025-06-26

REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma An open-label randomized phase II-III study

Not yet recruitingCTIS2024-516709-22-00

Centre Hospitalier Regional Universitairemetastatic colorectal cancer carcinoma

Target: 94Updated: 2025-10-08

Phase 3

Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non-infectious uveitis. FOCUS: treatment FOr Corticosteroid dependent UveitiS

RecruitingCTIS2023-505112-38-00

Assistance Publique Hopitaux De Parisand pan-uveitis, posterior, recently active non-infectious intermediate

Start: 2024-07-01Target: 120Updated: 2025-04-22

CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancers

RecruitingCTIS2023-509761-21-00

Centre Hospitalier Regional UniversitaireMetastatic colorectal cancer

Start: 2024-07-08Target: 174Updated: 2024-08-28

Randomized double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid - (RITUX-MMP)

Active, not recruitingCTIS2024-514885-38-00

Centre Hospitalier Universitaire Rouensevere forms of mucous membrane pemphigoid

Start: 2019-07-11Target: 130Updated: 2025-10-20

Phase 4

Patient Walking Rehabilitation Program with osteoarthritis of the hip or knee helped by a one-off anti-inflammatory treatment (pilot cohort study with short walking objectives) - PERIPATEI

RecruitingCTIS2022-502018-10-00

University Hospital Of Clermont-FerrandIdiopathic osteoarthritis of the hip or knee

Start: 2023-11-07Target: 55Updated: 2026-01-16

Treatment of anaemia after caesarean with intravenous versus oral iron and postpartum depression: a multicentric randomized open-labelled controlled trial (IRON-DEP)

RecruitingCTIS2023-503283-17-00

Assistance Publique Hopitaux De ParisWomen who delivered by caesarean and have a moderate postpartum iron deficiency anaemia defined by 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL within 72h after delivery and a ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% (Measured after postoperative Hb level measurement)

Start: 2025-10-22Target: 2860Updated: 2025-07-02